Tag: (NASDAQ:GTHX)

December 20, 2018

G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib

G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced positive topline data showing multi-lineage myelopreservation benefits in its randomized, double-blind,...
November 27, 2018

G1 Therapeutics Releases Phase 2 Data

Trilaciclib was tested in combination with chemotherapy and the checkpoint inhibitor Tecentriq in first-line small cell lung cancer patients.
November 27, 2018

G1 Therapeutics Announces Positive Myelopreservation Data

G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced positive topline data from its randomized, double-blind, placebo-controlled Phase 2 trial evaluating...
October 22, 2018

8 Top Gains and Losses at 2018’s ESMO Event

Big Pharma players and smaller oncology-focused companies alike were among the presenters at the annual meeting, which runs from October...